Pantethine

Summary

Pantethine (CHEMBL2104786) is a phase-3 clinical-stage small-molecule nutraceutical (ATC A11HA32); indicated across 1 condition including hyperlipoproteinemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A11HA32
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 554.7 Da · C22H42N4O8S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104786
Name	Pantethine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	452306
ChEBI	CHEBI:31959
ATC	A11HA32
Molecular formula	C22H42N4O8S2
Molecular weight	554.7
InChIKey	DJWYOLJPSHDSAL-ROUUACIJSA-N

SMILES: CC(C)(CO)[C@H](C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@@H](C(C)(C)CO)O)O

IUPAC name: (2R)-N-[3-[2-[2-[3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyldisulfanyl]ethylamino]-3-oxopropyl]-2,4-dihydroxy-3,3-dimethylbutanamide

ChEBI definition: An organic disulfide that consists of two molecules of pantothenic acid linked by amide bonds to a cysteamine disulfide bridging group.

Pharmacological roles (ChEBI): nutraceutical, coenzyme.

Also known as: D-pantethine, NSC-759269, Pantethine, PANTETHINE, D-Pantethine, pantethine

Patent coverage: 83 distinct patent families (136 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hyperlipoproteinemia	3	MONDO:0037748	MONDO:0037748

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01811082	PHASE3	COMPLETED	Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).